HealthcareServices

Global Eosinophilic Asthma Industry Trends and Market Forecast 2026–2030

February 24, 2026February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the eosinophilic asthma market from 2026–2035 with trusted insights from The Business Research Company

How is the Eosinophilic Asthma Market size predicted to change over the forecast window of 2026–2035?

The eosinophilic asthma market has seen rapid expansion in recent years. It is anticipated to increase from $3.16 billion in 2025 to $3.71 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.4%. The historical growth of the market can be linked to factors such as a poor response to inhaled steroids, an increase in asthma prevalence, the identification of eosinophil biomarkers, higher hospital asthma admissions, and the burden of chronic respiratory diseases.

The eosinophilic asthma market is anticipated to experience significant expansion over the next few years. It is projected to reach $6.92 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.9%. This expected growth during the forecast period is fueled by advancements in precision asthma treatments, the enlargement of the biologic drug pipeline, the implementation of biomarker-based diagnosis, the development of personalized respiratory care, and the expansion of specialty clinics. Prominent trends observed in the forecast period include the increasing uptake of biologic therapies, a heightened focus on severe asthma phenotypes, a surging demand for targeted immunotherapy, the proliferation of specialized respiratory clinics, and a strong emphasis on mitigating exacerbation rates.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

Which Drivers Are Contributing To The Expansion Of The Eosinophilic Asthma Market?

The anticipated increase in smoking habits is projected to drive the expansion of the eosinophilic asthma market. Smoking habits are defined as consistent patterns or actions involving tobacco product usage, including aspects like frequency, setting, and duration, frequently shaped by psychological, social, and environmental influences. This increase in smoking can be attributed to several factors, including heightened stress, focused advertising by tobacco firms, insufficient knowledge regarding health dangers, and societal acceptance of smoking in particular cultural settings. Treatment for eosinophilic asthma works by diminishing airway inflammation and enhancing lung function, thereby potentially promoting smoking cessation by easing the breathing problems that frequently compel individuals to keep smoking. For example, data from November 2025, provided by the Office for National Statistics, a UK-based government agency, showed that the proportion of women in Great Britain reporting e-cigarette use rose from 8.5% in 2023 to 10.0% in 2024. Furthermore, daily e-cigarette consumption was most prevalent among those aged 25 to 34 years and 35 to 49 years in Great Britain, reaching 9.3% and 9.5% respectively, with an observed increase in both age groups since 2023. Consequently, the escalating smoking rates are fueling the eosinophilic asthma market.

What Segment Classifications Make Up The Eosinophilic Asthma Market?

The eosinophilic asthma market covered in this report is segmented –

1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma

2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma

2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma

What Trends Are Driving The Growth Trajectory Of The Eosinophilic Asthma Market?

Leading companies within the eosinophilic asthma market are developing innovative drugs to target specific immune pathways, lessen inflammation, and improve patient outcomes through personalized treatment options. A monoclonal antibody is a synthetic molecule crafted in laboratories to mimic the immune system’s capacity to combat harmful pathogens such as viruses and bacteria. These are produced by fusing a particular antibody-producing cell with a cancer cell, allowing for the generation of large quantities of identical antibodies. For instance, in August 2024, AstraZeneca plc, a UK-based biopharmaceutical company, announced that Fasenra received approval from China’s National Medical Products Association, a China-based government agency, for the treatment of severe eosinophilic asthma. It is specifically indicated for patients with severe eosinophilic asthma, a condition characterized by high levels of eosinophils, which can lead to inflammation and worsening asthma symptoms. This is a monoclonal antibody that targets and depletes eosinophils through a unique mechanism. Fasenra enhances the immune system’s ability by binding to the IL-5 receptor on eosinophils to reduce eosinophil levels in the blood and tissues. The dosing regimen involves an initial loading phase followed by maintenance doses. Patients usually receive injections every four weeks for the first three doses, followed by every eight weeks thereafter.

Which Key Market Players Are Investing In Expansion And Innovation Within The Eosinophilic Asthma Market?

Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol‑Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, Bayer AG, Eli Lilly and Company, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Cipla Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Kirin Co. Ltd., UCB S.A., 4D Pharma plc, MorphoSys AG, Avalo Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Eosinophilic Asthma Market?

North America was the largest region in the eosinophilic asthma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Eosinophilic Asthma Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21184&type=smp

Browse Through More Reports Similar to the Global Eosinophilic Asthma Market 2026, By The Business Research Company

Allergic Rhinitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergic-rhinitis-global-market-report

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795